发明名称 Azaindazole amide compounds as CCR1 receptor antagonists
摘要 Disclosed are CCR1 inhibitor compounds of the formula (I): which are useful in the treatment of autoimmune and other diseases. Also disclosed a pharmaceutical compositions containing the same, and methods of making and using same.;
申请公布号 US8871786(B2) 申请公布日期 2014.10.28
申请号 US201113643325 申请日期 2011.04.26
申请人 Boehringer Ingelheim International GmbH 发明人 Huber John D.
分类号 C07D471/04;A61K31/437;A61P19/02;A61P37/08 主分类号 C07D471/04
代理机构 代理人 Morris Michael P.;Bottino Anthony P.
主权项 1. A compound of the formula (I): wherein Ar is phenyl, naphthyl or heteroaryl chosen from aziridinyl, thienyl, furanyl, thiazolyl, isothiazolyl, isoxazolyl, oxazolyl, oxadiazolyl, pyrazolyl, thiadiazolyl, tetrazolyl, pyrrolyl, imidazolyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, pyranyl, benzofuranyl, indolyl, quinoxalinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, quinolinyl, quinazolinyl, naphthyridinyl, indazolyl, triazolyl and purinyl each bearing from 0-4 substituents chosen from halogen, C1-5 alkyl, C3-7 cycloalkyl, C1-5 haloalkyl, cyano, nitro, —SR, —OR, —SO2R, —SO2NRR1, —NR1—SO2R, —CO2—R, —NRR1, —NR2C(O)—R, —C(O)NRR1, aryl ring and 5- or 6-membered heteroaryl ring each ring optionally substituted with 1 or 2 substituents chosen from halogen and C1-5 alkyl; R, R1, and, R2 are each independently hydrogen or C1-5 alkyl; X is halogen; or a pharmaceutically acceptable salt thereof.
地址 Ingelheim am Rhein DE